Dr. Michael McCullar, PhD - CEO, RegCell - Restoring Self Tolerance To The Immune System

Send us Fan MailDr. Michael McCullar, PhD is Chief Executive Officer  of RegCell ( https://regcellbio.com/ ), a biotechnology company has developed a best-in-class proprietary platform that allows the generation of epigenetically reprogrammed antigen-specific regulatory T-cells (Tregs) that are stable in vivo and maintain a high degree of functionality (S/F-Epigen-Tregs) to restore immune tolerance and ultimately reverse autoimmune disorders as well as the limitations with transplantation.Dr. McCullar has a wealth of experience in the biotech and pharmaceutical industries, spanning more than two decades. Throughout his career, he has been involved in various aspects of drug development and played pivotal roles in the success of several pharmaceutical companies. Dr. McCullar formerly served as the CEO of OnQuality Pharmaceuticals, where he provided executive leadership to this targeted oncology supportive therapy company focused on developing pioneering medications tailored to address the intricacies of cancer treatment-related toxicities. Before that, he was Chief Operating Officer at Tolero Pharmaceuticals, where he had a prominent role in the company’s acquisition by Sumitomo Dainippon Pharma and also served as the Senior Vice President of Business Development at Astex Pharmaceuticals, during it’s acquisition by Otsuka Pharmaceuticals. Dr. McCullar has held several high-level executive positions at SuperGen, showcasing his commitment and upward career path within the company. His journey at SuperGen culminated in the role of Senior Vice President of Strategy and Operations, where his expertise paved the way for the U.S. Food and Drug Administration (FDA) approval of Dacogen as a treatment for myelodysplastic syndromes, and the acquisition of Astex Therapeutics, which resulted in the formation of Astex Pharmaceuticals, Inc.Dr. McCullar holds a Ph.D. in Toxicology from the University of California, Riverside and an MBA from the W.P. Carey School of Business at Arizona State University.#MichaelMcCullar #RegCell #RegulatoryTCells #Tregs #AutoimmuneDisorders #Transplantation #ShimonSakaguchi #ImmuneSystem #SelfAntigens #Tolerance #AntiInflammatoryCytokines #AntigenPresentingCells #Thymus #BoneMarrow #Anergy #AntigenSpecificTregs #AntigenTargeting #Homing #EpigeneticEditing #Reprogramming #AutologousManufacturing #Japan #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show